Below is the due diligence report on the Healthcare Sector that highlights Harvard Apparatus Regenerative Technology Inc. (NASDAQ: HART), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Aeterna Zentaris Inc. (NASDQ: AEZS), and KaloBios Pharmaceuticals Inc. (NSADQ: KBIO). The due diligence reports includes a company overview, market overview, financial review and analyst summary.
***Special Situation Alert***
Our new biotech alert of the week is Actinium Pharmaceuticals (NYSE-MKT: ATNM)
-ATNM- “On track to submit the Iomab-B IND filing in the fourth quarter of 2015”
-Institutional ownership on the rise- follow the smart money
-Lower end of the 52 week range
-An absolutely great article about one of ATNM’s drug candidates and what they are trying to accomplish: http://www.bionapcfa.com/2015/11/actinium-pharmaceuticals-platform.html?m=1
Getting their house in order
An excerpt from the cover letter of a 14A filing on November, 13th 2015, should get you started on your due diligence and give everyone a good idea of why we like ATNM right now.
Dear Actinium Shareholders,
“Above all else, we wish to thank all our shareholders, new and old, for their faith in our ability to execute on our strategy and generate shareholder value. As outlined in our letter to you in July, we acknowledge that we have faced challenges this year, specifically with manufacturing process and scale-up issues pertaining to Iomab TM -B. We are pleased to have overcome these obstacles and now with these challenges behind us and our organization stronger than ever before, we are eager to embark on a new era for Actinium. We have made significant strides with Iomab-B and are on track to file the IND by year end. With respect to Actimab-A, we are excited to be near the conclusion of the Phase 1 portion of the clinical trial, which will be highlighted at the 57 th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida on December 4 – 8, 2015. We are eager to begin the Phase 2 portion of the trial as we are very well-positioned competitively. We look forward to the future with confidence in our strategy as we progress into 2016. We will strive to deliver sustainable results that will drive growth and generate shareholder value as we continue to drive the business forward in 2016 and beyond.
Key Achievements in 2015″
• On track to submit the Iomab-B IND filing in the fourth quarter of 2015
• Completed the majority of the Phase 1 clinical trial for Actimab-A, the final three confirmatory patients are now enrolling which will enable the Phase 2 trial to start in 2016
• Actimab-A’s positive results imply leadership position in the renewed race for CD-33 targeting drugs in AML
• Started work on an exciting new indication for one of our drug candidates with proof of concept studies expected in 2016
• Successfully labeled an antibody with Actinium-225 creating an exciting new pipeline candidate with broad hematology applications
• Strengthened our development team with key senior level hires in place ahead of the upcoming Phase 3 clinical trial for Iomab-B and Phase 2 trial for Actimab-A next year
***Much Anticipated IND Filing to Enable Initiation of Iomab-B’s Single, Pivotal, Phase 3 Clinical Trial in 2016
In 2015, we successfully addressed our manufacturing challenges, bolstered our development team in key areas and established a clear regulatory pathway for Iomab-B. In addition, we further strengthened our intellectual property portfolio with a provisional patent application for infusion administration of Iomab-B. These achievements give us great confidence as we look past our planned fourth quarter IND filing toward to the upcoming pivotal, Phase 3 clinical trial. We have hired and will continue to hire key professionals to our clinical, project management, manufacturing, quality control and regulatory teams to ensure that we execute the Iomab-B trial in the most efficient and timely manner. With these new members firmly on board, we are confident in our ability to execute and look forward to providing you, our shareholders, with regular updates on our progress as we seek to obtain regulatory approval for Iomab-B and deliver this important, potentially breakthrough therapy to patients.
Full 14A filing- http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11007049
Actinium Pharmaceuticals Inc (NYSE: ATNM) Check the company website for investor presentation and more in-depth information about their drug pipeline.
*Actinium Pharmaceuticals (ATNM) is a biopharmaceutical company specializing in the development of cancer drugs. They are the leading biotechnology company developing alpha particle linked antibodies to treat cancer.
52 week range- $1.52 – $6.65
We will be back with much more soon. I think the timing is perfect here.
Our reports/releases are a commercial advertisement and are for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. Broadstreetalerts.com has been compensated by star media, llc thirty thousand dollars via bank wire for a two day investors relations campaign.
PLEASE NOTE: Broadstreetalerts.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold Broadstreetalerts.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Broadstreetalerts.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Broadstreetalerts.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead Broadstreetalerts.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Broadstreetalerts.com is compliant with the Can Spam Act of 2003. Broadstreetalerts.com does not offer such advice or analysis, and Broadstreetalerts.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, Broadstreetalerts.com has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, Broadstreetalerts.com com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. Broadstreetalerts.com is not responsible for any claims made by the companies advertised herein, nor is Broadstreetalerts.com responsible for any other promotional firm, its program or its structure.